NCT03071198 is a NA clinical trial of TME in Rectum Cancer, sponsored by Harbin Medical University.

Who is sponsoring NCT03071198?

NCT03071198 is sponsored by Harbin Medical University.

What drugs are being tested in NCT03071198?

Interventions in NCT03071198: TME, Concurrent chemo-radiotherapy, neoadjuvant CT, adjuvant CT.

What condition does NCT03071198 study?

NCT03071198 studies Rectum Cancer.

Is NCT03071198 still recruiting?

NCT03071198 is currently status unknown. Last updated 7 March 2017.

Last reviewed 2017-03-07 · How we verify

NCT03071198

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Effect of Neoadjuvant Hierarchical Treatment Based on Chemotherapy

Status unknown NA Last updated 7 March 2017

What this trial tests

NA trial testing TME in Rectum Cancer in 1 participant. Status unknown.

Timeline

1 March 2017

Primary endpoint
30 September 2018

30 September 2021

Quick facts

Lead sponsor	Harbin Medical University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	1
Start date	1 March 2017
Primary completion	30 September 2018
Estimated completion	30 September 2021
Sites	1 location across China

Drugs / interventions tested

TME
Concurrent chemo-radiotherapy — full drug profile →
neoadjuvant CT — full drug profile →
adjuvant CT — full drug profile →

Conditions studied

Rectum Cancer — all drugs for Rectum Cancer →

Sponsor

Harbin Medical University

Who can join

Adults 20 to 70, any sex, with Rectum Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Clinical effect of neoadjuvant hierarchical treatment based on chemotherapy for T3-4N0-2M0 middle and lower rectal cancer

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of TME

Trials testing the same drug.

NCT05763927 — Neoadjuvant Therapy for Locally Advanced Rectal Cancer With Fruquintinib, Toripalimab and SRT · Phase 2 · unknown
NCT05253846 — Short-course Radiotherapy Followed by Consolidation Chemotherapy. 2021-001206-29 · Phase 2 · active not recruiting
NCT04664504 — A Prospective Phase II Study of Individualized Neoadjuvant Chemoradiotherapy for Rectal Cancer Based on Recurrence Risk · Phase 2 · unknown
NCT04747951 — Total Neoadjuvant Therapy in Rectal Cancer Treatment · Phase 4 · unknown
NCT04543695 — A Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer · Phase 2 · unknown

Other recruiting trials for Rectum Cancer

Currently open trials in the same condition.

NCT07137000 — The Effect of Art Therapy in Patients Undergoing Colorectal Cancer · NA · active not recruiting
NCT06812728 — Neoadjuvant FOLFIRINOX and Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer Patients · Phase 2 · recruiting
NCT06530303 — Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer · Phase 1, PHASE2 · recruiting
NCT06805045 — Image-Guided Surgery In The Treatment Of Rectal Cancer (AR_CRC) · NA · recruiting
NCT06116019 — Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS) · recruiting

Other Harbin Medical University trials

Trials by the same sponsor.

NCT07471815 — Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mecha · Phase 2 · active not recruiting
NCT07187674 — The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonr · NA · not yet recruiting
NCT07161791 — Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer · Phase 1, PHASE2 · not yet recruiting
NCT07033624 — Cardiovascular Risk Early Screening and Warning in Harbin : A Prospective Cohort Study · not yet recruiting
NCT06947148 — The Impact of Comprehensive Post Hospital Management Based on DHI on Cardiac Function in Patients With HF · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03071198 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Harbin Medical University
Last refreshed: 7 March 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03071198.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing